Butterfly Network to Report Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Feb 18, 2025--
Butterfly Network, Inc. (NYSE: BFLY) ('Butterfly'), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:00 am ET.
Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast before the market opens on February 28 to discuss the financial performance and operational progress.
The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Events & Presentations.
Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time:
US domestic callers: 1-877-300-8521
International callers: 1-412-317-6026
Conference ID: 10195836
Or use the Call me™ link for instant online telephone access to the event
(active 15 minutes prior to scheduled start time):
After the live webcast, the webcast will be archived on Butterfly's Investor Relations page.
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world's first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore's Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly's innovations have also been recognized by Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements.
Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: .
Heather Getz
Chief Financial and Operations Officer, Butterfly
[email protected] Halper
LifeSci Advisors (IR Representative)
646-876-6455
INDUSTRY KEYWORD: SOFTWARE RADIOLOGY BIOTECHNOLOGY HARDWARE HEALTH MEDICAL DEVICES HEALTH TECHNOLOGY TECHNOLOGY
SOURCE: Butterfly Network, Inc.
Copyright Business Wire 2025.
PUB: 02/18/2025 08:05 AM/DISC: 02/18/2025 08:06 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
17 minutes ago
- Associated Press
FPT Proposes Public-Private Partnership Model to Develop Vietnam's Digital Healthcare Ecosystem
HANOI, Vietnam--(BUSINESS WIRE)--Jun 6, 2025-- Global IT services provider FPT and Pharma Group jointly hosted the Healthcare Innovation Forum - HIF 2025. The event served as a multi-stakeholder dialogue platform with a spotlight on breakthrough innovations in science, technology, and AI to accelerate healthcare advancements and drive digital transformation in public health services. This press release features multimedia. View the full release here: FPT Proposes Public-Private Partnership Model to Develop Vietnam's Digital Healthcare Ecosystem The Forum was attended by Vietnam Deputy PM H.E. Le Thanh Long, key government officials, and international guests including U.S. Ambassador Marc Knapper, Swiss Ambassador Thomas Gass, former German Vice Chancellor Dr. Philipp Rösler, and representatives from Japan, Singapore, and Harvard Medical School. Vietnam Deputy PM H.E. Le Thanh Long stressed the urgent need to reform healthcare, outlining five strategies: accelerate digitalization with AI and IoT; boost biotech research; strengthen the pharmaceutical sector; foster public–private partnerships; and expand international cooperation for a modern digital health system. Mr. Darrell Oh, Chairman of Pharma Group, said: 'Pharma Group, representing the innovative pharmaceutical industry, reaffirms its commitment to supporting Vietnam in achieving the goals outlined in Vision 2045. Realizing this ambition requires a unified, multi-stakeholder approach. Only through sustained collaboration can policy be translated into impactful, lasting improvements in public health. Investing in healthcare is, ultimately, an investment in Vietnam's most vital asset: its people.' Dr. Truong Gia Binh, FPT Chairman, stated: 'To accompany Vietnam's new era of advancement, the healthcare sector must achieve breakthroughs in three areas: regulation, innovation, and public–private collaboration. We must shift from restrictive thinking to viewing regulation as a driver of national competitiveness, ensuring faster access to new medicines, like in the U.S. or Japan. Vietnam can become a hub for AI-powered clinical trials and drug development, leveraging its strong tech talent with 1 million IT workers, aiming for half to be AI-proficient. Public–private partnerships must connect hospitals, pharmaceutical firms, and healthcare professionals through shared data platforms. Just as Vietnam rose to global prominence in software, it can now aim to lead in innovative pharmaceuticals - one of the world's most advanced industries.' AI in Pharma: A Global Trend and an Opportunity for Vietnam Recent data shows 80% of pharma professionals use AI for drug discovery, with 95% of companies investing in it; and AI can cut drug development time from 5-6 years to one. In clinical trials, AI can reduce costs by 70% and timelines by 80%. Mr. Hoang Viet Anh, FPT Digital Chairman and FPT Telecom Chairman, FPT Corporation, underscored: 'AI and GenAI are transforming the pharmaceutical industry, with key benefits including accelerating new drug development and enhancing clinical trials across the value chain.' He also called this a key moment for digital transformation, outlining an AI roadmap for Vietnam's pharmaceutical sector through 2028. Plans include a centralized data system and AI lab pilots in 2025, blockchain trials in 2026 to fight counterfeit drugs, and a 20% reduction in drug trial time by 2027, aiming to become ASEAN's leading AI hub by 2028. Achieving Resolution 57 and National Goals for Healthcare Breakthroughs As Vietnam pursues its 2045 high-income vision, healthcare emerges as a key pillar for quality of life, social security, and sustainable growth. The round table discussing critical factors to achieve Resolution 57 objectives emphasized three key messages. Firstly, AI and big data drive healthcare innovation, enabling faster drug development and personalized care. Secondly, bold legal and institutional reforms are essential to match tech advances, including streamlined approvals and flexible data regulations. Lastly, strong public-private collaboration is vital to build a sustainable innovation ecosystem connecting tech firms, hospitals, research institutes, and startups. Mr. Vu Anh Tu, FPT Chief Technology Officer, commented: 'AI is set to transform healthcare, and by creating a centralized health data infrastructure and leveraging AI and data analysis for new drug trials, Vietnam can establish advanced clinical research centers, shorten timelines, reduce costs, and expand public access to new medicines. Technology can also enable new healthcare delivery models like telemedicine hospitals to improve primary healthcare and expand public access.' He further stated: 'FPT is ready to collaborate with startups, major enterprises, and global AI research institutions to address key challenges through AI. This approach will mobilize domestic and international resources to drive breakthroughs in this new era.' About Pharma Group Founded in 1998, Pharma Group represents the innovative pharmaceutical industry in Vietnam, comprising 20 member companies from Europe, the United States, and Japan. These companies share a mission to ensure timely and sustainable access to high-quality, safe, and innovative medicines for Vietnamese patients. Pharma Group operates under the European Chamber of Commerce in Vietnam (EuroCham) and is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). It works closely with policymakers and healthcare stakeholders in Vietnam and globally to advance sustainable health policies and initiatives, reduce the time to patient access, and build a favorable and attractive investment environment. About FPT Corporation FPT Corporation is Vietnam's leading technology group, pioneering digital transformation and leading in technology and telecommunications solutions and services. FPT supports clients in over 30 countries and territories in achieving their business development strategies through technology. In the healthcare sector, FPT is committed to building a remote healthcare platform and a comprehensive digital medical ecosystem that delivers fast, convenient, and integrated services for regulators, medical institutions, pharmaceutical companies, pharmacy networks, and the public. Leveraging over a decade of AI research and development, FPT actively integrates AI technologies to enhance healthcare quality and expand access to personalized medical services, particularly through telemedicine and real-time patient health monitoring. In pharmaceuticals, FPT advances the sector by digitizing R&D processes, deploying Advanced Pharmacy Omni-Channel Systems, and developing comprehensive drug management platforms connecting patients, doctors, and pharmacies through electronic medical records. Prominent clients include Long Chau Pharmacy, Hitachi Medical Devices, Olympus, MedAdvisor, Zuellig Pharma, and BrightInsight. View source version on CONTACT: Media Contact Mai Duong (Ms.) FPT Corporation FPT Software PR Manager [email protected] KEYWORD: VIET NAM SOUTHEAST ASIA ASIA PACIFIC INDUSTRY KEYWORD: TECHNOLOGY CLINICAL TRIALS HEALTH TECHNOLOGY TELEMEDICINE/VIRTUAL MEDICINE SOFTWARE HEALTH PHARMACEUTICAL DATA MANAGEMENT ARTIFICIAL INTELLIGENCE SOURCE: FPT Corporation Copyright Business Wire 2025. PUB: 06/06/2025 07:13 AM/DISC: 06/06/2025 07:12 AM
Yahoo
19 minutes ago
- Yahoo
Could BigBear.ai Stock Turn a $25,000 Investment Into $1 Million?
offers a wide range of artificial intelligence solutions. While it does possess some attractive potential, its business hasn't taken off -- at least, not yet. 10 stocks we like better than › Many investors see a lot of potential in (NYSE: BBAI). The data analytics company is sometimes compared to Palantir Technologies (NASDAQ: PLTR) in that it can serve many industries, has secured government contracts, and is utilizing artificial intelligence (AI) to expand upon its opportunities. But is that comparison really justified? Could -- with its small-cap size of just $1 billion or so today -- become the next hot growth stock? And if so, does it have the potential to turn a $25,000 investment into $1 million over the long term? For a $25,000 investment in to grow to $1 million or more, the stock would need to grow by 40 times. That would mean its market cap needs to reach more than $45 billion. To earn such a valuation, the company would need to show significant improvements on both its top and bottom lines. The good news is that many companies are spending heavily on AI in order to enhance their decision-making capabilities and improve overall efficiency. There are serious opportunities for to capitalize on those trends in the long run. The problem is that while offers various AI solutions (including predictive intelligence, cybersecurity, modeling, and digital identity management), that hasn't translated into significant revenue growth. The company's growth rate over the past few years has averaged just under 4%. This year, management is forecasting revenue between $160 million and $180 million. The low end of the forecast would be almost flat relative to the $158 million it achieved in 2024. If it hits the top end of the range, its revenue will grow by around 14%. While that's decent, it's not the type of AI-powered growth that investors may be expecting or that may be necessary for the stock to take off. has been securing defense-related contracts similar to those pursued by Palantir, which has been a key partner for governments around the world. Most recently, announced a collaboration with Hardy Dynamics, which provides the U.S. Army with "advanced AI capabilities." But while they may offer somewhat comparable services, that doesn't mean that these two businesses are the same. What has made Palantir a hot AI stock is the company's relentless growth. It has been expanding both its commercial and government businesses at impressive rates. During the first three months of 2025, Palantir's U.S. commercial revenue grew by 71% year over year, and its U.S. government revenue was up by 45%. meanwhile, may not even generate 10% growth across its entire business this year. Further, while Palantir is profitable, is nowhere near breaking even. It posted a net loss of $62 million in the first quarter -- more than the $35 million in revenue it brought in. Until can show that it can generate the type of impressive growth that Palantir has achieved, there's little reason to expect that it can become a top growth stock. While does possess potential, so do many of the numerous other companies that are also offering AI solutions. Ultimately, it's the results that matter. Given its low valuation, may seem like a stock worth taking a chance on. After all, if its growth rate does accelerate, the stock could soar. If it were to simply get back to its 52-week high of $10.36, it would more than double in value from where it is today. But at the same time, the stock could also end up plummeting back toward its 52-week low of just over $1.16 if it continues to underwhelm investors with its results. When it comes to such a volatile stock, it's hard to predict which direction it will go. So while may be an intriguing stock to watch, it's not going to be a suitable holding for most investors. And there's little reason at this stage to expect that it has the potential to be a millionaire-making investment. Before you buy stock in consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. Could Stock Turn a $25,000 Investment Into $1 Million? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Why CoreWeave, Inc. (CRWV) Skyrocketed Today
We recently published a list of . In this article, we are going to take a look at where CoreWeave, Inc. (NASDAQ:CRWV) stands against other Wednesday's best-performing stocks. CoreWeave rallied for a fourth consecutive day on Wednesday, jumping 8.39 percent to close at $163.10 apiece following the unveiling of record-breaking performance results using Nvidia Corp.'s latest Grace Blackwell chips. In a statement, CoreWeave, Inc. (NASDAQ:CRWV) said that it used 2,496 Nvidia GPUs on its AI-optimized cloud platform, making its submission the largest-ever benchmarked under MLPerf. A close-up of a digital cloud, signifying the expansive reach of the software-as-a-service solution. CoreWeave, Inc. (NASDAQ:CRWV) said that the test was 34x larger than the only other submission from a cloud provider. 'AI labs and enterprises choose CoreWeave because we deliver a purpose-built cloud platform with the scale, performance, and reliability that their workloads demand,' said CoreWeave, Inc. (NASDAQ:CRWV) Chief Technology Officer Peter Salanki. 'These MLPerf results reinforce our leadership in supporting today's most demanding AI workloads,' he added. The unveiling followed the company's new $7-billion deal with Applied Digital Corporation (NASDAQ:APLD), which covered two 15-year lease agreements, under which the latter will deliver 250 megawatts of critical IT load to host its artificial intelligence (AI) and high-performance computing (HPC) infrastructure at its Ellendale, North Dakota data center campus. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
